To ensure that a patient’s test is billed to their 2024 health benefits, testing must be started before the end of the year. For exome, genome, or Xpanded testing, if you do not expect parental samples to be received before the end of the year, please contact us at support@genedx.com to determine how to proceed.
We have a shared vision: Bringing new therapies to patients, faster—with GeneDx biopharma solutions.
We’re pleased to announce the launch of GeneDx Discover, a first-of-its-kind visualization tool to support the drug development process.
Powered by GeneDx’s unmatched database, the new solution visualizes de-identified, aggregated genetic and real-world data to enable a deeper understanding of the characteristics of target patient populations of interest.
With Discover, GeneDx now offers an end-to-end solution for pharma companies.
Leverage our unmatched dataset to find the clinicians and patients you’re looking for.
Use clinicogenomic data to inform the drug discovery process and cohort builders to inform market insights.
Joint programs aimed at increasing access, accelerating diagnosis, and finding patients.
Clinician & patient outreach program
We partnered with GeneDx on clinical trial outreach for one of our genetic epilepsy programs. The recruitment initiative was to send a letter direct to diagnosed patients and their ordering clinician, informing them about our trial, for which they may be eligible. We were highly impressed working with GeneDx on this initiative and the level of professionalism from start to finish. The entire process was a true collaboration and we will absolutely partner with GeneDx again on clinical trial recruitment for all of our upcoming genetic epilepsy trials.”
—Director of Natural History Studies
The partner
Mahzi Therapeutics is developing multiple novel therapies for rare pediatric-onset neurodevelopmental conditions. One of the orphan drugs in their pipeline is being developed to treat patients with CHD2 deficiency.
The problem
The phenotypes of patients with CHD2 deficiency are not well documented, and there is limited data to inform clinical trial development for these patients.
Our solution
GeneDx developed patient clustering analyses and identified clinical subtypes with high and low age at testing, as well as a clinical subtype with very low rates of seizures.
Our impact
Empowered with these insights, Mahzi could expand the scope of patients eligible for their trial, optimize their trial arms, and increase the likelihood of their drug succeeding in phase I/II trials.
The GeneDx biopharma team works with industry partners to understand their unique challenges, align with their goals, and provide tailored solutions. It all starts with a conversation.
Get in touch to partner with us today: fill out this form or contact us at biopharma@genedx.com
